Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability, packaging for supporting said stability, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability, packaging for supporting said stability, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Packaged formulations of gamma-hydroxybutyrate having improved dissolution and chemical stability, packaging for supporting said stability, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing comprising an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing comprising niacin, aspirin and a lipid-lowering drug other than niacin.

Abstract: The present invention relates to a closure system including a thermochromic tamper-control means of color that is irreversibly modified in the event of the temperature of the closure system being raised above a threshold temperature, said closure system comprising a polymer matrix having incorporated therein at least one thermochromic pigment of color that is irreversibly modified after said closure system has been exposed to a temperature close to or above a threshold temperature. The invention also relates to a method of preparing a thermochromic closure system, and to receptacles provided with said system.

Abstract: A precursor for the preparation of a material with optical properties modifiable under the action of at least one external parameter, comprising a component A constituted by polymerizable monomers or oligomers, a component B comprising one or several liquid crystals with low molecular weights or polymers and having a type of molecular order that is nematic, cholesteric or smectic or having polymorphism, and at least one surface agent C whose molecules have an affinity both for component A and for component B, and comprising simultaneously one or several chemical groups that can attach chemically to the constituents of component A, and one or several chemical groups comprising a mesogenic portion compatible with the mesomorphic phase of component B, so as to control the interfacial properties between components A, and B during polymerization.

Abstract: The invention concerns a precursor for preparing a material with optical properties capable of being modified by the action of at least one external parameter. Said precursor comprises: a component A consisting of polymerisable monomers or oligomers; a component B comprising one or several low molecular liquid crystals or polymers and having a nematic, cholesteric or smectic molecular arrangement or exhibiting polymorphism; said precursor further comprising: at least a surfactant C whereof the molecules have an affinity both for component A and for component B, and simultaneously comprise one or several chemical groups capable of chemically bonding with the constituents of component A and one or several chemical groups comprising a mesogenic part compatible with the mesomorphous phase of component B, so as to control the interface properties between said components A, B during polymerisation, for preparing a material exhibiting a spatial modulation of its optical properties.